ClinicalTrials.gov
public full text
Public Domain
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
The primary objective of the study was to demonstrate the efficacy of dupilumab as a monotherapy in participants ≥12 years to \<18 years of age with moderate-to-severe atopic dermatitis (AD). The secondary objective of the study was to assess the safety of dupilumab as a monotherapy in participants ≥12 years to \<18 years of age with moderate-to-severe AD.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)#982638
- Dupilumab De-escalation in Pediatric Atopic Dermatitis#835866
- Severity bands for atopic dermatitis measures: analysis from adult dupilumab randomized clinical trials / Andreas Wollenberg, Eric L. Simpson, Yael A. Leshem, Alain Taïeb, Norito Katoh, Jingdong Chao, Ana B. Rossi, Amy H. Praestgaard#783932
- The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients#1370466
- Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis#807778
Record · ID 1383898
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive